IL160050A0 - Probiotic lactobacillus casei strains - Google Patents

Probiotic lactobacillus casei strains

Info

Publication number
IL160050A0
IL160050A0 IL16005002A IL16005002A IL160050A0 IL 160050 A0 IL160050 A0 IL 160050A0 IL 16005002 A IL16005002 A IL 16005002A IL 16005002 A IL16005002 A IL 16005002A IL 160050 A0 IL160050 A0 IL 160050A0
Authority
IL
Israel
Prior art keywords
lactobacillus casei
probiotic lactobacillus
casei strains
strains
probiotic
Prior art date
Application number
IL16005002A
Other languages
English (en)
Original Assignee
Alimentary Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alimentary Health Ltd filed Critical Alimentary Health Ltd
Publication of IL160050A0 publication Critical patent/IL160050A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/245—Lactobacillus casei
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL16005002A 2001-07-26 2002-07-26 Probiotic lactobacillus casei strains IL160050A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IE20010715 2001-07-26
IE20010699 2001-07-26
IE20010700 2001-07-26
IE20010706 2001-07-26
IE20010712 2001-07-26
PCT/IE2002/000112 WO2003010299A1 (en) 2001-07-26 2002-07-26 Probiotic lactobacillus casei strains

Publications (1)

Publication Number Publication Date
IL160050A0 true IL160050A0 (en) 2004-06-20

Family

ID=27517571

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16005002A IL160050A0 (en) 2001-07-26 2002-07-26 Probiotic lactobacillus casei strains

Country Status (9)

Country Link
US (1) US20030113306A1 (enExample)
EP (1) EP1409643A1 (enExample)
JP (1) JP2005508150A (enExample)
CN (1) CN1556853A (enExample)
BR (1) BR0211438A (enExample)
CA (1) CA2454805A1 (enExample)
IL (1) IL160050A0 (enExample)
PE (1) PE20030283A1 (enExample)
WO (1) WO2003010299A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7182943B2 (en) * 2002-05-15 2007-02-27 UNIVERSITé LAVAL Method and system for modulation of microbial cell characteristics
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US20040265279A1 (en) * 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
US20050271643A1 (en) * 2003-08-14 2005-12-08 Iryna Sorokulova Bacterial strains, compositions including same and probiotic use thereof
WO2005030230A1 (en) * 2003-09-30 2005-04-07 Probiomics Limited Compositions and methods for treatment or prevention of psoriasis and related disorders
US8871266B2 (en) * 2003-10-01 2014-10-28 Commonwealth Scientific & Industrial Research Organisation Probiotic storage and delivery
AU2004275438B2 (en) * 2003-10-01 2008-05-29 Commonwealth Scientific & Industrial Research Organisation Probiotic storage and delivery
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US7785635B1 (en) * 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
JP4938005B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティックであるラクトバシラス
BRPI0611492B1 (pt) 2005-05-31 2021-10-13 Mars, Incorporated Bifidobactéria probiótica felina
ES2333259T3 (es) * 2005-11-21 2010-02-18 Bioatlantis Limited Composiciones destinadas a mejorar la salud intestinal y el rendimiento en animales que comprenden beta-glucanos y alfa-fucanos.
CA2673465A1 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal
CN105796607A (zh) * 2007-02-28 2016-07-27 Mjn 美国控股有限责任公司 用于儿童或婴幼儿的含有灭活益生菌的产品
CN101144065B (zh) * 2007-09-03 2011-11-09 江南大学 一种耐过氧化氢、清除自由基的抗氧化干酪乳杆菌及其用途
EP2065048A1 (en) * 2007-11-30 2009-06-03 Institut Pasteur Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
WO2010013143A2 (en) * 2008-08-01 2010-02-04 Institut Pasteur Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
JP5852558B2 (ja) * 2010-03-26 2016-02-03 株式会社明治 腸管免疫の抑制剤のスクリーニング方法
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
US9011909B2 (en) 2010-09-03 2015-04-21 Wisconsin Pharmacal Company, Llc Prebiotic suppositories
EP3569690B1 (en) 2011-12-01 2024-08-28 The University of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
WO2014128737A1 (en) * 2013-02-25 2014-08-28 Italchimici S.P.A. Dietary food for the treatment of inflammatory bowel diseases
CN104031855A (zh) * 2013-03-08 2014-09-10 任发政 干酪乳杆菌及其应用以及功能食品组合物及其制备方法
CN104651245B (zh) * 2013-11-15 2017-10-13 景岳生物科技股份有限公司 用于治疗微小核糖核酸病毒感染的益生菌组合物及其用途
US20150139968A1 (en) * 2013-11-15 2015-05-21 Genmont Biotech Inc. Probiotic composition for treating picornavirus infection and its use thereof
US20150209468A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Hygiene article containing microorganism
US20150209469A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Web Comprising a Microorganism-Containing Fibrous Element and Methods for Making Same
US20150209392A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Filaments Comprising a Microorganism and Method for Making Same
WO2016008084A1 (zh) * 2014-07-15 2016-01-21 王国全 自体来源乳酸菌的制造方法及系统
US20160354507A1 (en) 2015-06-07 2016-12-08 The Procter & Gamble Company Article of commerce containing absorbent article
CN108135945A (zh) * 2015-06-22 2018-06-08 哈佛大学校长及研究员协会 固有层调节性t细胞的诱导
US20170020750A1 (en) 2015-07-23 2017-01-26 The Procter & Gamble Company Patch containing microorganism
CN105087439B (zh) * 2015-08-19 2017-12-12 内蒙古农业大学 一种高抗阿莫西林干酪乳杆菌及其选育方法
EP3341082B1 (en) 2015-08-27 2020-12-16 PrecisionBiotics Group Limited Bifidobacterium longum
TWI598103B (zh) * 2016-08-22 2017-09-11 景岳生物科技股份有限公司 改善困難梭狀桿菌感染症狀的發酵乳酸桿菌ｇｍｎｌ－２９６組合物及方法
US11813297B2 (en) 2017-03-23 2023-11-14 Katholieke Universiteit Leuven, Ku Leuven R & D Probiotic Lactobacillus casei strain and its uses
AU2017100632A4 (en) * 2017-05-29 2017-07-06 Bgi Shenzhen An oral liquid probiotic formulation and method of preventing and/or treating arthritis
IT201700101704A1 (it) * 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
CN109486700A (zh) * 2018-08-31 2019-03-19 石家庄君乐宝乳业有限公司 副干酪乳杆菌n1115预防结肠炎的应用及相应的益生菌粉、应用
CN110591950B (zh) * 2019-09-23 2021-05-28 江南大学 一株可以提高肠道il-22表达量的干酪乳杆菌
CN110893195B (zh) * 2019-09-30 2023-03-14 内蒙古伊利实业集团股份有限公司 一种具有缓解肠道炎症功能的副干酪乳杆菌et-22
CN110669697B (zh) 2019-10-31 2022-07-15 微康益生菌(苏州)股份有限公司 一种高产短链脂肪酸的干酪乳杆菌、培养方法及其应用
CN118020940A (zh) * 2019-11-29 2024-05-14 内蒙古伊利实业集团股份有限公司 副干酪乳杆菌k56提升肠道细菌感染抗性和肠道免疫力的应用
CN112869170B (zh) * 2019-11-29 2023-05-23 伊利伊诺科技(上海)有限责任公司 可提高胃肠道免疫能力的益生菌益生元营养组合物及应用
CN112375722B (zh) * 2021-01-18 2021-04-13 山东中科嘉亿生物工程有限公司 一种改善过敏的干酪乳杆菌lc-12及其产品、应用
CN113088468B (zh) * 2021-04-09 2022-06-03 中国农业大学 干酪乳杆菌Ma.GLRGJ 1及其应用
CN117089505B (zh) * 2023-10-20 2024-03-19 杭州微致生物科技有限公司 一种副干酪乳杆菌vb306及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55113718A (en) * 1979-02-27 1980-09-02 Yakult Honsha Co Ltd Antitumor agent
GB2261372A (en) * 1991-11-15 1993-05-19 Gregor Reid Lactobacillus and skim milk compositions for prevention of urogenital infection
MXPA99007378A (es) * 1997-02-11 2005-04-19 Entpr Ireland Cepas probioticas de lactobacillus salivarius y agentes antimicrobianos obtenidos a partir de lasmismas.
EP0904784A1 (en) * 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
AUPQ415899A0 (en) * 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases
ATE391509T1 (de) * 2000-12-18 2008-04-15 Probio Health Von lactobacillus casei ke01 stamm abgeleitete probiotische verbindungen

Also Published As

Publication number Publication date
CN1556853A (zh) 2004-12-22
JP2005508150A (ja) 2005-03-31
US20030113306A1 (en) 2003-06-19
BR0211438A (pt) 2004-07-13
PE20030283A1 (es) 2003-05-01
WO2003010299A1 (en) 2003-02-06
CA2454805A1 (en) 2003-02-06
EP1409643A1 (en) 2004-04-21

Similar Documents

Publication Publication Date Title
IL160050A0 (en) Probiotic lactobacillus casei strains
IL160048A0 (en) Probiotic bifidobacterium strains
AU2003265296A8 (en) Lactobacillus strains and uses therefor
AU7616001A (en) Probiotic recolonisation therapy
AU6079201A (en) Lactobacillus reuteri glucosyltransferase
ZA200209087B (en) Use of lactobacillus casei in immunostimulatory peptides.
IL173692A0 (en) Bacterial strains, compositions including same and probiotic use thereof
HUP0401017A3 (en) Combination of probiotics
EP1718154A4 (en) PROBIOTIC DOG LACTOBACILLA
HUP0200205A3 (en) Lactobacillus strains preventing diarrhoea pathogenic bacteria
AU2001256435A1 (en) Use of lactobacillus casei in immunostimulatory compositions
IL200443A (en) Mutant genes of Lactobacillus bulgaricus without beta-galactosidase activity
HUP0402024A3 (en) Solid composition containing bacillus-type non-pathogenic bacterial spores
EP1450610A4 (en) PROBIOTIC COMPOSITIONS
AU2002344447A1 (en) Bacterium of the genus bifidobacterium and fermented foods using the same
AU2003224355A8 (en) Lactobacillus fermentum strain and uses thereof
AU2001254856A1 (en) Lactococcus lactis genome, polypeptides and uses
AU2003250503A8 (en) Probiotic therapies using lactobacillus reuteri
ZA200407456B (en) Lactobacillus strains.
AU2003261572A1 (en) Lactobacillus casei lc2w strain and its use in antihypertensive aspect
PL362753A1 (en) New strain of lactobacillus paracasei
AU2003225362A1 (en) Lactobacillus acidophilus ky1909
SG97174A1 (en) Lactobacillus rhamnosus strain and uses thereof
PL349543A1 (en) Novel strain of lactic bacteria lactobacillus bulgaricus
PL344117A1 (en) Novel strain of lactobacillus rhamnosus bacterium